Back to Newsroom

Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases

SAN DIEGO, Jan. 7, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.

Click here to read more